ASH: Celgene's pomalidomide shows durable response in late multiple myeloma
This article was originally published in Scrip
Executive Summary
Celgene's pomalidomide appears to produce durable responses in multiple myeloma patients who have failed previous therapies, suggest data from the pivotal Phase III MM-003 presented this week at the American Society of Hematology meeting in Atlanta.